35 results about "Lactobacillus helveticum" patented technology

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention belongs to the technical field of microbiological detection, and discloses a PCR primer combination for detecting mixed microorganisms in a food fermentation process and a detection method thereof. The primer combination comprises a primer pair used for detecting pediococcus pentosaceus, a primer pair used for detecting plant lactobacillus, a primer pair used for detecting lactobacillus mucus fermentation, a primer pair used for detecting bacillus amyloliquefaciens and a primer pair used for detecting lactobacillus acidophilus. The primer pair is at least one of a primer pair for detecting lactobacillus helveticus and a primer pair for detecting acetobacter pasteurianus. The primer combination or the kit containing the primer combination can realize species level specific detection of microorganisms, and can be used for qualitatively / quantitatively detecting food and key functional microorganisms in the food fermentation process, so that the dynamic change of a target flora in the fermentation process is quickly and accurately monitored.

The invention discloses a lactobacillus helveticus metaplasm complex and application thereof in constipation treatment, and relates to the technical field of constipation treatment, a specific lactobacillus helveticus KLDS 1.1 1105 strain is adopted, and metaplasm is prepared through fermentation and spray drying. The invention further provides a three-layer embedded compound structure. The outer layer is composed of pitaya powder and prune powder and is used for rapidly relaxing the bowels; the middle layer contains a pomegranate peel extract and is used for regulating flora; the core is colon-targeted lactobacillus helveticus metagen and inulin and is used for long-acting regulation. According to the compound, through the multi-target synergistic effect, gastrointestinal hormone is regulated, related signal channels are activated, the function of intestinal pace-making cells is promoted, and generation of short-chain fatty acid is increased, so that the constipation symptom is rapidly relieved, meanwhile, the intestinal function is fundamentally repaired, and the intestinal microecology is improved. The product disclosed by the invention is good in stability, high in safety and suitable for preparing medicines or functional foods for treating functional constipation.

The invention discloses lactobacillus helveticus 5-1 separated from fermented milk and application of the lactobacillus helveticus 5-1. The lactobacillus helveticus 5-1 has the highest viable count in 12 hours at the end of the logarithmic phase; the lactobacillus helveticus 5-1 has better acid production capacity and acid resistance; the tolerance of the lactobacillus helveticus 5-1 is strong under the bile salt concentration of 0.3%; the thallus extract of the lactobacillus helveticus 5-1 has strong capability of removing DPPH (1, 1-diphenyl-2-picrylhydrazyl); the lactobacillus helveticus 5-1 is high in exopolysaccharide (EPS) production capacity. The lactobacillus helveticus 5-1 with high activity, strong oxidation resistance, excellent acid and cholate resistance and high exopolysaccharide yield is separated, screened and cultured from the traditional fermented milk in Xinjiang, so that the blank of multifunctional and high-performance autonomous strains in the prior art is filled; the application efficiency and the stability of the compound in probiotic preparations and functional foods are improved.

The present invention relates to the use of the Lactobacillus helveticus BGRA43 strain for the prevention and / or treatment of liver diseases and / or liver disorders, preferably metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (N AFLD), and / or for the reduction of liver steatosis. The formulation, preferably for peroral administration, comprising the L. helveticus BGRA43 strain. The formulation comprising the L helveticus BGRA43 strain, which is preferably a probiotic food product intended for human consumption. Lyophilizate of the L helveticus BGRA43 strain, comprising the L. helveticus BGRA43 strain at a concentration from 108 to 1013 CFU / g.

The application discloses a bifendate biomimetic oral nanodelivery system based on lactobacillus helveticus exosomes and a preparation method and application thereof. The preparation method comprises the following steps: extracting lactobacillus helveticus exosomes from a lactobacillus helveticus culture solution by adopting a method combining continuous differential centrifugation and microporous membrane filtration; and mixing the lactobacillus helveticus exosomes with bifendate, and performing ultrasonic treatment and incubation treatment to prepare the lactobacillus helveticus exosome-bifendate biomimetic oral nanodelivery system. The application successfully extracts a lactobacillus helveticus source exosome with high yield and expandable advantages for the first time, and improves the clinical limitations of high cost and low productivity of animal source and plant source exosomes as oral delivery carriers; meanwhile, the prepared lactobacillus helveticus exosome-bifendate biomimetic oral nanodelivery system combines the natural characteristics of exosomes and the high biological safety of probiotics, and can realize the balance between the oral delivery performance and the biological safety of the nanocarrier.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The invention belongs to the field of microorganisms, and particularly provides application of Lactobacillus helveticus ZJUIDS11: relieving and improving ozostomia (breath), and also provides application of the Lactobacillus helveticus ZJUIDS11 as well as application of the Lactobacillus helveticus ZJUIDS11 as an anti-inflammatory agent. The preservation number of the lactobacillus helveticus ZJUIDS11 is CGMCC (China General Microbiological Culture Collection Center) NO.24761, and the preservation number of the lactobacillus helveticus ZJUIDS11 is CGMCC NO.24761. The lactobacillus helveticus ZJUIDS11 can be used for inhibiting hydrogen sulfide and methyl mercaptan.

The invention discloses lactobacillus helveticus IMAU16360 with ACE (Angiotensin Converting Enzyme) inhibitory activity and application of the lactobacillus helveticus IMAU16360 in fermented milk, and belongs to the field of microorganisms. The lactobacillus helveticus IMAU16360 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36567, the preservation time is November 11, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The commercial leavening agent PYS-010 and the lactobacillus helveticus IMAU16360 are compounded according to the ratio of 1: 1, the pH and acidity change trend of the compounded group in the storage period is consistent with that of a control group, the compounded group is fused into an existing process system, and an existing production line does not need to be replaced; the elasticity and viscosity of a single strain fermented product are improved, so that the product is fuller in taste; on the premise that the basic taste is not influenced, the fermented milk has ACE inhibitory activity; meanwhile, a relatively high level of viable count is maintained, and good market value is achieved.

The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the amelioration of symptoms associated with rosacea-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus helveticus, (ii) Lactobacillus plantarum, (iii) Bifidobacterium longum, and (iii) Streptococcus thermophilus; and (b) at least one plant-based, antioxidant-rich source of fiber.

This invention relates to the field of health food, and discloses a high-yield direct-inoculation starter culture for antihypertensive peptides and its application in the preparation of antihypertensive yogurt. The starter culture is prepared by mixing *Streptococcus thermophilus* WHH1590, *Lactobacillus delbrueckii* subsp. bulgaricus WHH699, and *Lactobacillus helveticus* WHH2580 in a ratio of 90-100:15-25:1. This starter culture, after mixing, exhibits a significant synergistic effect, significantly enhancing the ability of microorganisms to decompose proteins and significantly increasing the content of antihypertensive peptides in yogurt. When using the starter culture of this application to ferment yogurt, it achieves the technical advantages of a short fermentation cycle, high yield of antihypertensive peptides, and high ACE inhibitory activity. Yogurt prepared with the starter culture provided by this application not only ensures a high yield of antihypertensive peptides but also possesses excellent sensory qualities, with a thick texture, delicate structure, and no unpleasant flavor. Yogurt prepared with the starter culture provided by this application exhibits higher thermal stability and safety compared to existing technologies.

Provided in the present application are a compound probiotic for preventing and treating colitis, and the use thereof. The compound probiotic for preventing and treating colitis consists of a Pediococcus acidilactici PA53 strain and a Lactobacillus helveticus LH76 strain. The two probiotics can cooperate with each other, boost each other, and achieve a synergistic effect in terms of preventing and treating colitis, which is specifically exhibited in alleviating the weight loss caused by colitis, reducing the disease activity index, restoring colon length, ameliorating inflammatory factor dysregulation and oxidative stress response caused by colitis, and increasing the content of short-chain fatty acids in the intestines. In a case where the same bacterial dosage is used, the compounding of the two strains exhibits significantly improved efficacy in preventing and treating colitis compared with strain interventions using either strain alone.

The invention discloses a complex microbial inoculant for camel milk fermentation and application of the complex microbial inoculant. The complex microbial inoculant is prepared from the following strains in parts by weight: 1 to 10 parts of lactobacillus plantarum KC28, 20 to 50 parts of leuconostoc mesenteroides SHU1396, 0.1 to 0.5 part of lactobacillus acidophilus DSM9126, 1 to 10 parts of lactobacillus helveticus R0052 and 10 to 20 parts of kluyveromyces marxianus D53749. According to the complex microbial inoculant for camel milk fermentation, through selection of various strains, camel milk fermentation can be rapidly achieved, the fermentation time is short, and the fermented camel milk after fermentation is pure in taste, sour, light in sweet taste, heavy in milk flavor, free of mutton smell and fishy smell and excellent in flavor and taste.

The invention belongs to the technical field of microorganisms, and particularly relates to a synbiotics preparation of lactobacillus helveticus as well as a preparation method and application of the synbiotics preparation. The synbiotics preparation of the lactobacillus helveticus, provided by the invention, is a microcapsule preparation prepared by taking the lactobacillus helveticus as probiotics and sialylated breast milk oligosaccharide as prebiotics and sequentially embedding by adopting sodium alginate and chitosan; wherein the lactobacillus helveticus is lactobacillus helveticus HL88. The lactobacillus helveticus HL88 adopted by the invention has better cracking activity on the sialylated breast milk oligosaccharide, and can effectively improve the utilization efficiency of the sialylated breast milk oligosaccharide. Furthermore, the lactobacillus helveticus and the sialylated breast milk oligosaccharide are subjected to composite embedding, so that the synergistic metabolism effect can be achieved, and the brain development process is effectively promoted. Therefore, the invention can provide a treatment thought for improving the brain development retardation, and can also provide a technical basis for developing probiotic medicines for promoting brain development.

The invention relates to leuconostoc mesenteroides capable of assisting weight management and application, a product and a method thereof, and relates to the technical field of probiotic compositions.The probiotic composition for improving obesity is prepared from, by weight, 10-60 parts of lactobacillus rhamnosus PB-LR76, 10-60 parts of lactobacillus helveticus HH-LPH17, 10-80 parts of lactobacillus casei PB-LC39 and 10-60 parts of lactobacillus fermentum HH-LF392. The feed additive comprises the following components in parts by weight: 10-60 parts of leuconostoc mesenteroides subsp. Mesenteroides MUM502 and 10-60 parts of lactobacillus reuteri PB-LR09. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for improving obesity is prepared, and a safe and effective new method is provided for weight management of obese people.

The application discloses strains for preventing and treating Parkinson's disease and compositions, applications and products thereof, and relates to the technical field of microorganisms.The application provides three strains of human milk origin, namely Lactobacillus helveticus LV-20, Lactobacillus plantarum LPP8 and Lactobacillus fermentum PL-15.The application also provides a composition capable of preventing and treating Parkinson's disease.The three strains can preferably prevent and treat Parkinson's disease.The composition can significantly improve motor dysfunction (such as static tremor, muscle rigidity, bradykinesia, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive impairment, relieve sleep disorders, inhibit neural inflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, improve constipation and regulate intestinal flora composition, and has a wide application prospect as a probiotic or synbiotic product for treating and preventing Parkinson's disease.

The application discloses a high-ethanol-tolerant Lactobacillus helveticus and application thereof. The Lactobacillus helveticus is named Lactobacillus helveticus FJL4-UV4, and the preservation number is GDMCC NO.62957. The Lactobacillus helveticus is obtained by ultraviolet mutagenesis of a wild Lactobacillus helveticus FJL4 isolated from a Chinese rice liquor fermentation liquor. The Lactobacillus helveticus FJL4-UV4 provided by the application overcomes the defects of the wild Lactobacillus helveticus FJL4 in high-ethanol tolerance, and promotes the generation of ethyl lactate under high-ethanol conditions. The Lactobacillus helveticus FJL4-UV4 is used for solving the problem of low ethyl lactate content in the fermentation liquor in the Chinese rice liquor production process, and the ability of the Lactobacillus helveticus FJL4-UV4 in increasing the ethyl lactate content in the fermentation liquor is significantly improved compared with the wild type.

This invention discloses a strain of *Lactobacillus helveticus* and its applications, relating to the field of microbial technology. The *Lactobacillus helveticus* strain disclosed in this invention (… Lactobacillus helveticus The sample, ProfMIC-226, was deposited at the China Center for Type Culture Collection on August 3, 2022, with accession number CCTCCNO:M20221224. Experiments have shown that ProfMIC-226 possesses anti-aging, cell proliferation-promoting, moisturizing, and skin barrier-repairing functions, and can be used in pharmaceutical preparations.

The invention belongs to the technical field of fermented food, and particularly relates to a preparation method of chili sauce with traditional flavor characteristics. The preparation method provided by the invention comprises the step of using a compound strain combination, wherein the compound strain combination is prepared from lactobacillus casei CCFM1074, lactobacillus rhamnosus NM-94, lactobacillus plantarum TSP05 and lactobacillus helveticus RE-78. According to the method, the fermentation period is shortened to 5-8 days through bacterial strain function synergy, and the production efficiency is improved compared with that of a traditional process; the product is rich in volatile flavor substances and characteristic flavor substances such as esters and alcohols, and is matched with the traditional flavor; the total acid of the product reaches 2.74-3.01 g / 100g, the pH value is stabilized at 3.86 + / -0.02, chemical preservatives are not needed, the process is controllable, and the method is suitable for industrial large-scale production.

The invention discloses walnut fermented milk based on double regulation and control of compound fermentation of lactobacillus helveticus as well as a preparation method and application of the walnut fermented milk, and belongs to the field of microbial fermented foods and food processing. The preservation number of the lactobacillus helveticus is CGMCC No.31947, and the lactobacillus helveticus is compounded with a conventional leavening agent for use. When the ratio of protein to fat in the walnut milk is 1: 1.5, the system is most stable, the tissue state is most uniform and delicate, and the flavor loss is less, so that the stability of the system can be remarkably improved, and the mellow flavor and fermentation aroma of walnuts can be retained. When the lactobacillus helveticus and the leavening agent are compounded according to the proportion of 2: 1, the blood sugar improving function of the walnut fermented milk can be remarkably improved, the inhibition rate of alpha-amylase is 44%, and the inhibition rate of alpha-glucosidase reaches 75%. The product is moderate in sour and sweet taste and uniform and stable in tissue state, has the characteristic flavor of the walnut fermented milk, depends on the components of walnuts per se in stability, is not additionally added with other components, and is a natural and stable product.

This invention belongs to the field of microbial technology, specifically relating to the application of *Lactobacillus helveticus* ZJUIDS12 in preventing and treating microplastic-induced injuries in pets. This invention discloses the application of *Lactobacillus helveticus* ZJUIDS12 in the preparation of drugs for preventing and treating microplastic-induced injuries in pets. The accession number for *Lactobacillus helveticus* ZJUIDS12 is CGMCC NO.23997. The prevention and treatment of microplastic-induced injuries in pets includes: preventing intestinal damage caused by microplastics and preventing fetal growth restriction caused by microplastics.

The invention belongs to the technical field of microorganisms, and in particular relates to lactobacillus helveticus IOB726 with an effect of reducing blood fat as well as a segmented fermentation preparation method and application of the lactobacillus helveticus IOB726. The invention discovers that the lactobacillus helveticus IOB726 has the effect of reducing blood fat for the first time. The lactobacillus helveticus IOB726 bacterial powder and the preparation thereof are prepared by adopting segmented liquid state fermentation for the first time, not only is the bacterial activity improved, but also an inulin component is added into a second-stage fermentation culture medium, so that a carbon source is provided for the growth of the lactobacillus helveticus IOB726, and the lactobacillus helveticus IOB726 is promoted to generate short-chain fatty acid in the fermentation metabolism process; the liver cholesterol synthesis can be inhibited, so that the hyperlipemia symptom can be improved. Besides, experimental results show that the lactobacillus helveticus IOB726 has an efficient blood fat reducing effect, has good acid resistance, bile salt resistance and gastrointestinal tract simulation tolerance, can play a role in human intestinal tracts, supplements strain resources of blood fat reducing probiotics, and shows a better blood fat reducing effect.

The present invention addresses the problem of providing a bacterium belonging to Lactobacillus helveticus, which has an excellent IFN production-inducing effect. The present invention relates to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN, and which induces the production of type I IFN at a level of 1.5 times or more as compared to that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445), and more particularly, to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN at a level of 1.5 times or more than that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445).

The application belongs to the field of food fermentation, and particularly relates to a low post-acid direct-vat yogurt starter and a preparation method. The application provides a low post-acid direct-vat yogurt starter, which comprises Streptococcus thermophilus NJ21 and Lactobacillus helveticus LH-08B; the preservation number of the Streptococcus thermophilus NJ21 is CCTCC NO.M2014250, and the preservation number of the Lactobacillus helveticus LH-08B is CCTCC NO.M2019013. The two bacteria are compounded according to a certain proportion to prepare the direct-vat yogurt starter, which is used for preparing yogurt as a starter, has a fast fermentation speed, and has weak post-acid and good quality.

The use of a heat-treated lactobacillus, which is Lactobacillus casei GMNL-143, Lactobacillus helveticus GMNL-164 or Lactobacillus rhamnosus GMNL-464, for the preparation of a medicament for inhibiting the adhesion of oral pathogenic bacteria, and a composition for inhibiting the adhesion of oral pathogenic bacteria.

To provide novel lactic acid bacteria and an immunostimulant using said lactic acid bacteria. [Solution] The present invention provides an immunostimulant comprising Lactobacillus helveticus, wherein Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of IgA production, and induction of IL-12 production.

The invention discloses application of lactobacillus helveticus CCFM1440 in relieving rheumatoid arthritis, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1440 is screened, the lactobacillus helveticus CCFM1501 can produce cell wall protease and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, which is specifically reflected in that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; according to the present invention, the content of pro-inflammatory cytokines such as IL-1beta, IL-6, IL-17A and TNF-alpha in the serum of the rheumatoid arthritis rat can be reduced, the content of arthritis specific antibodies and matrix metalloproteinase in the serum of the rheumatoid arthritis rat can be reduced, the intestinal flora of the rheumatoid arthritis rat can be improved, and the abundance of the bacillus thuringiensis and the Rombout can be reduced;

This invention provides a composition containing lactic acid bacteria and its use in lowering dihydrotestosterone and improving hyperandrogenemia. The composition can lower dihydrotestosterone and improve androgenemia. The lactic acid bacteria comprise *Lactobacillus helveticus* GKS3, *Lactobacillus brevis* GKL9, *Lactobacillus johnsonii* GKJ2, *Pediococcus acidilactici* GKA4, or a combination thereof.